Trial Comparing Effect of He/O2 to Medical Air on Pulmonary Function Disease - Full Text View

Sponsors and Collaborators:	Air Liquide SA Inamed
Information provided by:	Air Liquide SA
ClinicalTrials.gov Identifier:	NCT00801307

Purpose

This clinical trial will include healthy volunteers, COPD patients and asthmatic patients who will breathe He/O2 78:22, He/O2 65:35 and medical air consecutively in a randomised order.

Condition	Intervention	Phase
Asthma Chronic Obstructive Pulmonary Disease Healthy	Device: spirometer	Phase I Phase II

MedlinePlus related topics: Asthma COPD (Chronic Obstructive Pulmonary Disease)

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Diagnostic, Randomized, Single Blind (Subject), Dose Comparison, Crossover Assignment, Safety/Efficacy Study
Official Title:	A Single Site,Exploratory,Phase I/II,Randomised Trial Comparing the Effect of He/O2 Mixtures(He/O2 78:22 and He/O2 65:35) to Medical Air on Pulmonary Function in Moderate/Severe Asthma and COPD Patients and Healthy Volunteers

Further study details as provided by Air Liquide SA:

Primary Outcome Measures:

Inspiratory Capacity measured by spirometry at rest while breathing each He/O2 mixture compared to its measurement on medical air [ Time Frame: 30 mn ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Inspiratory Capacity measured by ergospirometry while breathing Pulmonary function parameters at rest, i.e., FEV1, FVC, FEF25-75, PEF and ERV while breathing each He/O2 mixture compared to medical air, [ Time Frame: 20 Mn ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	30
Study Start Date:	June 2008
Estimated Study Completion Date:	June 2009
Estimated Primary Completion Date:	March 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental He/O2 78:22	Device: spirometer According to the randomisation order, the appropriate medical gas cylinder with the pressure regulator will be connected to a humidifier to avoid the inhalation of very dry gas; the humidifier will be connected to the breathing bag; the flow of the medical gas will be adjusted individually for each subject/patient by the valve of the pressure regulator.
2: Experimental He/O2 65:35	Device: spirometer According to the randomisation order, the appropriate medical gas cylinder with the pressure regulator will be connected to a humidifier to avoid the inhalation of very dry gas; the humidifier will be connected to the breathing bag; the flow of the medical gas will be adjusted individually for each subject/patient by the valve of the pressure regulator.
3: Active Comparator Medical Air	Device: spirometer According to the randomisation order, the appropriate medical gas cylinder with the pressure regulator will be connected to a humidifier to avoid the inhalation of very dry gas; the humidifier will be connected to the breathing bag; the flow of the medical gas will be adjusted individually for each subject/patient by the valve of the pressure regulator.

Detailed Description:

Two types of measurements will be performed with each of the three evaluated gases:

pulmonary function measurements at rest to establish the resistance to airflow in a reproducible way, including the measurements of Inspiratory Capacity (IC), Forced Expiratory Volume in 1 second (FEV1), Forced Expiratory Flows (FEF) at different lung volumes (25 to 75% of the vital capacity), and Forced Vital Capacity (FVC),
Tidal Volume (TV) measured at rest and during light cycling exercise. The results of this study should be useful to evaluate the extent of influence on gas concentration, since none of the previous trials have been performed with He/O2 65:35, as well as the extent of influence on the lung disease, since none of the previous trials have been performed with asthmatic patients at various disease stages.

The working hypothesis is that when using He/O2 mixtures 78:22 and 65:35, the flow resistance decreases as compared to medical air because low density helium replaces nitrogen, thus resulting in a lower workload of breathing for asthmatic and COPD patients. For patients with reduced pulmonary function, this difference might result in greater Inspiratory Capacity.

That is why Inspiratory Capacity will be measured as primary efficacy criterion, but also Tidal Volume and other pulmonary function parameters on 3 types of subjects/patients :

healthy volunteers,
patients with moderate and severe persistent asthma,
patients with moderate and severe COPD.

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

All subjects/patients:
- Willing and able to complete the requirements of this study including the signature of the written informed consent,
- Able to complete the study in 5 working days or less,
- Able to perform pulmonary function tests
Healthy volunteers:
- Never smoker or subject who stopped smoking at least 6 months before selection (strictly less than 10 pack-years),
- Having pulmonary function tests within the normal range(according to predicted values for age, sex and height as referenced in ATS/ERS 1993 standards)
Patients with moderate/severe persistent asthma:
- Documented clinical diagnosis of moderate or severe persistent asthma (according to GINA 2006 guidelines),
- Stable asthma in the 4 weeks prior to selection as evidenced by no change in asthma medication, no treatment for asthma in an emergency,acute care setting and no admission to hospital for acute asthma

Patients with moderate / severe COPD:

Aged ≥ 45 and £ 80 years old,
Documented clinical diagnosis of moderate or severe COPD(according to GOLD 2006 guidelines),
With a smoking history of 10 pack-years or more,
Stable COPD in the 4 weeks prior to selection as evidenced by no change in COPD medication, no treatment for COPD in an emergency, acute care setting and no admission to hospital for COPD exacerbation

Exclusion Criteria:

Obese subject/patient having a Body Mass Index (BMI) > 35,
Past or present respiratory disease including being free from the common cold and rhinitis for at least 4 weeks before selection except asthma for asthmatic patients and COPD for COPD patients,
Daily need for 12 hours or more of long term oxygen therapy,
Pregnant or lactating woman,
Lack of efficient contraception according to CPMP/ICH 286/95 note 31,
Any contra-indication to perform pulmonary function tests or light cycling exercise,
Clinically significant or uncontrolled pathologic conditions which may interfere with the study procedures,
Drug abuse or psychic disorders resulting in an inability to fully understand the requirements of the study,
Legal status which prohibits informed consent,
Participation in any interventional clinical trial within 30 days prior to selection

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00801307

Locations

Germany, Gauting
Inamed Research GmbH & Co. KG	Recruiting
Robert-Koch-Allee 2, Gauting, Germany, 82131
Contact: Thomas Meyer, Dr. med. Tel: + 49 89 893569 13
Contact: Sabine Häussermann, PhD Tel: + 33 1 39 07 65 01 Sabine.HAUSSERMANN@airliquide.com
Principal Investigator: Thomas Meyer, Dr. med.

Sponsors and Collaborators

Air Liquide SA

Inamed

Investigators

Principal Investigator:

Thomas Meyer, Dr. med.

Inamed Research GmbH & Co. KG

More Information

No publications provided

Responsible Party:	Air Liquide SA ( Mr Philippe ROUAULT/Director CRCD )
Study ID Numbers:	ALMED-07-C2-012, EudraCT number 2007-004158-10
Study First Received:	December 2, 2008
Last Updated:	December 2, 2008
ClinicalTrials.gov Identifier:	NCT00801307
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Air Liquide SA:

evaluate Inspiratory Capacity (IC) measured by spirometry

Study placed in the following topic categories:

Hypersensitivity
Lung Diseases, Obstructive
Respiratory Tract Diseases
Bronchial Diseases
Lung Diseases

Hypersensitivity, Immediate
Asthma
Healthy
Respiratory Hypersensitivity
Pulmonary Disease, Chronic Obstructive

Additional relevant MeSH terms:

Immune System Diseases

ClinicalTrials.gov processed this record on February 12, 2009